Ceapro Reports Record Second Quarter 2014 Financial Results

Laying The Ground For New Heights

EDMONTON, ALBERTA-- Jul 30, 2014 - Ceapro Inc. (TSX VENTURE:CZO) -

• Total sales of $2,432,000 in Q2, 2014, an increase of 140% over Q2, 2013. Highest quarterly revenue in Ceapro's history
• Income from operations of $727,000 vs a loss of $155,000 in 2013
• Net profit of $630,000 vs net loss of $252,000 in 2013
• Record volume forecasts for 2014 for flagship product, avenanthramides
• BIOTECanada Gold Leaf Award as Emerging Company of The Year-Industry and Agriculture

Galectin Therapeutics Issues Statement on GR-MD-02 Development Program

NORCROSS, Ga., July 30, 2014  -- Galectin Therapeutics (GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced yesterday results of cohort 2 of its phase 1 clinical trial in patients with NASH with advanced fibrosis. While the results of the clinical trial were positive, the market reacted negatively to this report. We believe the reaction was fueled in part by certain commentary on social media sites and the Internet and we strongly disagree with these interpretations of our data. Our goal in commenting further at this juncture is to provide clarity and a helpful framework for investors on the long-term outlook of the company and our work toward developing potential therapies for NASH and liver fibrosis.

Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial

Treatment with VGX-3100 induces regression of precancerous cervical disease and clears HPV infection with robust T cell responses

PLYMOUTH MEETING, Pa., July 23, 2014 -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced successful results from its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 in women with biopsy-proven cervical intraepithelial neoplasia 2/3 (CIN2/3) associated with human papillomavirus (HPV) types 16 or 18. Treatment with VGX-3100, Inovio's HPV16/18-specific immunotherapy, resulted in histopathological regression of CIN2/3 to CIN1 or no disease, meeting the study's primary endpoint. In addition, the trial demonstrated clearance of HPV in conjunction with regression of cervical lesions. Robust T-cell activity was detected in subjects who received VGX-3100 compared to those who received placebo.

Biogen Idec Second Quarter 2014 Revenues Increase 40% to $2.4 Billion; Company Raises Financial Guidance for the Year

Growth Bolstered by Increased Adoption of TECFIDERA^® in New Markets Worldwide
Quarter Highlights include Approval of ELOCTATE^TM for Hemophilia A;
Positive Phase 3 Read Out for Multiple Sclerosis candidate Daclizumab HYP

CAMBRIDGE, Mass.-- Biogen Idec Inc. (BIIB) today reported second quarter 2014 results, including revenue of $2.4 billion, a 40% increase compared to the second quarter of 2013. Second quarter 2014 non-GAAP diluted earnings per share (EPS) were $3.49, an increase of 52% over the second quarter of 2013. Non-GAAP net income attributable to Biogen Idec for the second quarter was $829 million, an increase of 51% over the second quarter of 2013.